Bispecific Antibodies - The Bloodline with Blood Cancer United Podcast

Multiple myeloma can feel unfamiliar and overwhelming at first, but today’s advances tell a much brighter story.

In this episode, Dr. Andrew Yee of Massachusetts General Hospital explains what myeloma is, how it’s diagnosed, and why new treatment options, from four-drug regimens to CAR T-cell therapy and bispecific antibodies, are transforming patient outcomes. With enthusiasm and relatable analogies, he highlights how patients may progress from periods of significant challenges to reaching a level of stability and well‑being that allows them to live fully. This conversation offers clarity, confidence, and real optimism for anyone navigating myeloma.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by AbbVie Inc.; Bristol Myers Squibb; Genentech, A Member of the Roche Group; GSK plc.; Johnson & Johnson.

The post Facing Multiple Myeloma: A Guide to Choices, Care, and Confidence first appeared on The Bloodline with Blood Cancer United Podcast.

Non-Hodgkin lymphoma (NHL) can sound overwhelming, but what does it really mean for patients and families? In this episode, we speak to Dr. Jean Koff of Winship Cancer Institute of Emory University, who breaks down the big picture of NHL: what it is, how it’s an umbrella term for multiple subtypes, and what today’s treatments and tomorrow’s innovations could mean for you. From understanding subtypes and staging to exploring options like watchful waiting, chemotherapy, and cutting-edge immunotherapies, we cover what matters most: knowledge, clarity, and hope.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Supported by AbbVie Inc. and Genentech, A Member of the Roche Group.

The post The Big Picture on Non-Hodgkin Lymphoma: Treatments, Trends, and Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.

In this episode, we’re joined by Dr. Marc Hoffmann from The University of Kansas Cancer Center, to explore chronic lymphocytic leukemia (CLL)—what it is, how it’s treated today, and where research is headed. Dr. Hoffmann shares insights on treatment goals, side effect management, and the importance of shared decision making. We also touch on emerging therapies—including CAR T-cell therapy and bispecifics—and end with a message of hope for those navigating life after a CLL diagnosis.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by AbbVie Inc., BeOne Medicines and Genentech, A Member of the Roche Group.

The post Partnering in Care: Chronic Lymphocytic Leukemia (CLL) first appeared on The Bloodline with Blood Cancer United Podcast.

Primary Central Nervous System Lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain, spinal cord, or eyes. In this episode, Dr. Lakshmi Nayak of Dana-Farber Cancer Institute, helps us better understand this uncommon type of lymphoma.  From early signs and symptoms to diagnosis, treatment options, and the latest clinical trials, Dr. Nayak breaks it all down in a clear and compassionate way.

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by ONO Pharmaceutical

The post Breaking Down Primary CNS Lymphoma: From Rare Diagnosis to Growing Progress first appeared on The Bloodline with Blood Cancer United Podcast.

“If you have a rare disease, it’s not rare to you.”

In this episode, Dr. Naveen Pemmaraju of MD Anderson Cancer Center in Houston, TX, sheds light on the latest treatment advancements for myelofibrosis. The pace of scientific discovery for rare diseases is moving at a fast rate, resulting in better outcomes for myelofibrosis patients.

*This episode was recorded on Rare Disease Day, February 29, 2024

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: GSK plc.

The post Hope for a Rare Disease: Myelofibrosis first appeared on The Bloodline with Blood Cancer United Podcast.

Remarkable progress has been made in the treatment of myeloma over the past decade, giving patients and families much hope for the future. In this episode, we speak to Dr. Nishi Shah of Montefiore Einstein Comprehensive Cancer Center in New York City. While the wide variety of therapies available to patients are discussed, this episode also focuses on the newest, cutting-edge therapies for myeloma, such as CAR T-cell therapy and bispecific antibodies.  

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: AbbVie Inc.; Genentech, Inc. & Biogen; and Johnson & Johnson.

The post How New Therapies Are Changing The Future of Myeloma first appeared on The Bloodline with Blood Cancer United Podcast.